Experts from the Perelman School of Medicine at the University of Pennsylvania will be presenting data on the latest advances in cancer research and treatment at ASH’s annual meeting from December 11-14. Watch this space for press releases as embargoes lift during the meeting.
Experts
Experts from the Perelman School of Medicine are available to comment on a wide range of cancer research topics during the meeting by telephone or email. To arrange interviews, please contact Caren Begun at caren.begun@pennmedicine.upenn.edu or 267-408-9196. Follow us on Twitter at @PennMedNews and @PennMedBench.
News Releases
Abramson Cancer Center Researchers Present Latest CAR T Results at ASH Annual Meeting
Additional Highlighted Abstracts
- Acute Myeloid Leukemia (AML):
- Cost effectiveness analysis of venetoclax and azacitidine vs azacitidine in newly diagnosed AML patients ineligible for intensive chemo (Abstract #112)
- Real world survival outcomes of CPX-351 versus venetoclax and azacitadine for initial therapy in adults with AML (Abstract #613)
- First-in-human results on clinical activity in patients with relapsed / refractory multiple myeloma with immunocytokine modakafusp alfa (Abstract #898)
- Oncogenic signaling in B-Cell lymphoma with novel FBXO45-Gef-H1 Axis Controls (Abstract #711)
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.